Long-acting GLP1-RA have many favorable properties and have clear efficacy data for reducing cardiovascular risks, as well as safety data, for their use in patients with T2D at high cardiovascular risk, including the subset of patients with DKD
39 A prospective study of patients with moderate-to-severe plaque psoriasis showed a higher percentage of dermal T cells in psoriatic plaques when compared to control
Due to the rich fatty acid content, this ingredient may not be Malassezia folliculitis, or fungal acne, safe
From UV rays and air pollution to the metabolic demands of a busy workday, your cells are constantly working to stay balanced
Following the positive REDEFINE 1 Phase 3 data (published June 2025, PMID: 40544433), Novo Nordisk announced plans to file regulatory applications for CagriSema for obesity in the United States (FDA), European Union (EMA), and other major markets in 20252026
Originally approved for type 2 diabetes management, semaglutide's appetite-suppressing effects led to its development for standalone weight management, with studies showing 15-22% average weight reduction over 68 weeks in non-diabetic populations
